Understand your concerns, Evil, and it is true th
Post# of 148705
The earlier Basket Trial tested against a variety of cancers, making it too diffuse. The update for the mTNBC trial described a total of 28 patients, but those were pooled from three different studies:
Quote:
16 from our Compassionate Use Study, 10 from the Phase 1b/2 Study, and 2 from the Basket Study.
Critically, these studies used different doses.
So 60 patients in the Crc trial is not a lot, but it's a good deal more than earlier trials. Even with so few patients, the mTNBC should arguably have gotten Breakthrough Designation for the indication. I would bet that the CRC trial does win that Designation -- except that, in essence, I already have made that bet.